Calamos Advisors LLC Sells 36,137 Shares of CareDx, Inc (NASDAQ:CDNA)

Calamos Advisors LLC cut its position in CareDx, Inc (NASDAQ:CDNA) by 29.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 87,265 shares of the company’s stock after selling 36,137 shares during the period. Calamos Advisors LLC’s holdings in CareDx were worth $1,868,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Fred Alger Management LLC raised its stake in shares of CareDx by 30.8% during the 3rd quarter. Fred Alger Management LLC now owns 1,503,521 shares of the company’s stock worth $46,947,000 after acquiring an additional 353,919 shares in the last quarter. Geode Capital Management LLC grew its holdings in CareDx by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,227,724 shares of the company’s stock worth $38,343,000 after purchasing an additional 32,141 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of CareDx by 78.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 696,893 shares of the company’s stock worth $21,760,000 after purchasing an additional 306,222 shares in the last quarter. FMR LLC lifted its holdings in shares of CareDx by 802.4% during the 3rd quarter. FMR LLC now owns 625,550 shares of the company’s stock valued at $19,533,000 after purchasing an additional 556,230 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of CareDx by 2.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 499,480 shares of the company’s stock worth $15,596,000 after purchasing an additional 13,547 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. The Goldman Sachs Group upped their target price on CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. HC Wainwright reissued a “neutral” rating and set a $26.00 target price on shares of CareDx in a research report on Tuesday, January 14th. Wells Fargo & Company upgraded shares of CareDx from an “underweight” rating to an “equal weight” rating and cut their price target for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. Finally, BTIG Research lowered their price objective on shares of CareDx from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $28.33.

Insider Transactions at CareDx

In related news, Director Peter Maag sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the director now directly owns 330,024 shares in the company, valued at $8,250,600. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.90% of the company’s stock.

CareDx Trading Down 0.9 %

Shares of NASDAQ CDNA opened at $23.10 on Wednesday. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -8.56 and a beta of 1.87. CareDx, Inc has a 12 month low of $7.42 and a 12 month high of $34.84. The company has a 50 day simple moving average of $22.91 and a two-hundred day simple moving average of $25.14.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.11. The company had revenue of $82.88 million for the quarter, compared to the consensus estimate of $80.04 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm’s revenue for the quarter was up 23.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.43) EPS. Analysts forecast that CareDx, Inc will post -0.9 EPS for the current year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.